跳至主要内容
临床试验/CTRI/2022/03/041419
CTRI/2022/03/041419尚未招募4 期

Efficacy of Pistacia Lenticus Plant (Rumi Mastagi) inComparison to Levosupiride in Patients with Diabetic Gastroparesis A Double BlindRandomized Control Trial Study

dr ravikant1 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2022年4月15日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
38
试验地点
1
主要终点
1 improvement or changes in gastric transit time in diabetic gastroparesis time point - 8 weeks

研究概览

简要总结

This study is a randomised double blind parallel group trial to compare efficacy of  pistacia lenticus plant (RUMI MASTAGI) 500mg PO BD and levosupiride  25 mg PO BD in patients with diabetic gastroparesis: a pilot study, that will be conducted in  All India Institute Of Medical Sciences , Rishikesh .

The expected primary outcome measures will be improvement or changes in gastric transit time (scintigraphy) and Gastroparesis cardinal symptom index (GCSI) after 8 weeks of administration of lenticus gum.

The expected  secondary outcomes Improvemet in Hb1AC level ,improvement in lipid profile of patient , Improvement in general well being , Postprandial fullness/early satiety  after 8 week of ayurvedic medicine.( Mastig gum)

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant and Investigator Blinded

入排标准

年龄范围
19.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • all diabetic patients who are between 19 to 65 years of age with not meting exclusion criteria.

排除标准

  • diabetic patients with following conditions will be excluded from study- 1)Patient with PUD.
  • Irritable bowel syndrome.
  • Any known organic gastrointestinal or systemic diseases.
  • Diabetes in pregnancy lactation.
  • History of breast diseases.
  • Abnormalities of the menstrual cycle.
  • Previous abdominal surgery.
  • Mental disorders.
  • The use of drugs interfering with gastrointestinal motility.
  • The above diseases shall be ruled out by appropriate clinical assessment and patient case sheet records.

结局指标

主要结局

1 improvement or changes in gastric transit time in diabetic gastroparesis time point - 8 weeks

时间窗: 8 weeks

2 improvement in Gastroparesis cardinal symptom index (GCSI) - time point- 8 weeks

时间窗: 8 weeks

次要结局

  • Improvemnet in Hb1AC level(imrovement in lipid profile)

研究者

发起方
dr ravikant
申办方类型
Other [self]

研究点 (1)

Loading locations...

相似试验